Cellular Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
化疗引起的周围神经病变的细胞机制
基本信息
- 批准号:8866622
- 负责人:
- 金额:$ 16.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:Action PotentialsAddressAffectAfferent NeuronsAnalgesicsAnimal ModelAntineoplastic AgentsBehavioralBiological AssayCancer PatientCellular MechanotransductionChemotherapy-induced peripheral neuropathyDataDevelopmentDoseDrosophila genusElectrophysiology (science)EtiologyEventExposure toFunctional disorderFundingGene ExpressionGenerationsGeneticGenetic TranscriptionGleanGoalsHeterogeneityHourHumanHyperactive behaviorHyperalgesiaInvestigationIon ChannelKnowledgeLarvaMammalsMechanicsMediatingMembraneMitochondriaModelingMolecularNeuritesNeuronsNeuropathyNociceptionNociceptorsOrganismPaclitaxelPainPatientsPeripheralPeripheral NervesPharmaceutical PreparationsPharmacologyPositioning AttributeProtocols documentationResearchRodentRodent ModelSensorySiteSpinal GangliaSyndromeSystemTaxane CompoundTestingTimeUnited States National Institutes of HealthVinblastineVincaVinca AlkaloidsWorkallodyniacancer therapychannel blockerschemotherapyclinically relevantdosageeffective therapyfeedingmechanical allodyniamutantnovelpatch clampperipheral painpublic health relevanceresearch studyresponsetaxanetooltranslational approachtreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) and the associated pain represent a clinically relevant limit to patient treatment with anti-cancer
drugs. Currently, there is no effective treatment for CIPN. Enhanced excitability of peripheral sensory neurons is thought to contribute to the generation and progression of CIPN. By directly affecting membrane excitability, CIPN-causing chemotherapy drugs may enhance neuronal activity eventuating neuroexcitotoxicity and neuropathy. Whether a change in peripheral sensory neuron excitability is an early formative event of CIPN, though, is unknown. To date there have been few studies of peripheral sensory neurons directly investigating the cellular and molecular mechanisms by which chemotherapy drugs cause CIPN. Performing such experiments in mammals has been complicated by the heterogeneity of sensory neurons within the dorsal root ganglion, the site in mammals where nociceptors reside, and limitations in the experimental tractability of these complicated organisms. The group of PIs submitting this proposal is expert in investigating the cellular mechanisms underlying sensory transduction in peripheral sensory neurons in Drosophila, rodents, and humans. The current proposal combines complementary expertise in a relevant rodent model of peripheral pain with an unbiased approach in a model organism to investigate the cellular and molecular mechanisms of CIPN. The goals of this proposal are to demonstrate that understanding gleaned from investigating the effects of CIPN-causing chemotherapy drugs on peripheral sensory neurons in a simple model organism can be used in a rational manner to direct more complicated studies in a relevant mammalian system in order to provide a powerful means for determining the cellular and molecular mechanism of CIPN and facilitate the discovery of new analgesics for the treatment of CIPN. Our preliminary results suggest the novel hypothesis that CIPN is a result of the direct effect of chemotherapy drugs on the sensory transduction machinery of peripheral nociceptors. We accomplish the goals of this R21 by testing three specific aims: Aim 1; to characterize a novel Drosophila model of CIPN that will be employed to direct experiments in relevant mammalian models of pain. Aim 2: To define the cellular and molecular mechanisms that underlie the effects of vinblastine and paclitaxel on sensory neuron function. And Aim 3: To investigate whether peripheral application of vinblastine and paclitaxel can induce CIPN in mammals. The importance and significance of the worked proposed here is supported by the recent funding announcement from the NIH/NCI: PA-12-083, "Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R21)". It is expected that the successful completion of the experiments described in this proposal will provide key understanding of fundamental mechanisms that underlie CIPN and establish a research team well-positioned to use rational and translational approaches to develop novel treatment strategies to counter CIPN.
描述(由申请方提供):化疗诱导的周围神经病变(CIPN)和相关疼痛代表了患者抗癌治疗的临床相关限制
毒品目前,对于CIPN没有有效的治疗。外周感觉神经元的兴奋性增强被认为有助于CIPN的产生和进展。通过直接影响膜兴奋性,CIPN引起的化疗药物可能会增强神经元活性,从而导致神经兴奋性毒性和神经病。然而,外周感觉神经元兴奋性的变化是否是CIPN的早期形成事件尚不清楚。迄今为止,很少有外周感觉神经元直接研究化疗药物引起CIPN的细胞和分子机制的研究。在哺乳动物中进行这样的实验由于背根神经节内感觉神经元的异质性而变得复杂,背根神经节是哺乳动物中伤害感受器所在的部位,并且这些复杂生物体的实验易处理性受到限制。提交此提案的PI小组擅长研究果蝇、啮齿动物和人类外周感觉神经元中感觉转导的细胞机制。目前的建议结合了互补的专业知识,在相关的啮齿动物模型的外周疼痛与模型生物体的公正的方法,调查CIPN的细胞和分子机制。本提案的目标是证明从调查CIPN的影响中收集到的理解,在简单的模型生物体中引起外周感觉神经元上的化疗药物可以以合理的方式用于指导相关哺乳动物系统中更复杂的研究,以提供确定CIPN的细胞和分子机制的有力手段,并促进用于治疗CIPN的新镇痛剂的发现。CIPN。我们的初步结果表明,新的假设,CIPN是化疗药物的外周伤害感受器的感觉转导机制的直接影响的结果。我们通过测试三个具体目标来实现这一R21的目标:目标1;描述一种新的CIPN果蝇模型,该模型将用于指导相关哺乳动物疼痛模型的实验。目的2:明确长春碱和紫杉醇对感觉神经元功能影响的细胞和分子机制。目的3:研究外周应用长春碱和紫杉醇是否能诱导哺乳动物CIPN。本文提出的工作的重要性和意义得到了NIH/NCI最近的资助公告的支持:PA-12-083,“抗癌治疗(R21)周围神经损伤的生物机制”。预计本提案中描述的实验的成功完成将提供对CIPN基础的基本机制的关键理解,并建立一个能够使用合理和转化方法开发新的治疗策略来对抗CIPN的研究团队。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin Arthur Eaton其他文献
Benjamin Arthur Eaton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin Arthur Eaton', 18)}}的其他基金
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8016005 - 财政年份:2010
- 资助金额:
$ 16.45万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8420454 - 财政年份:2010
- 资助金额:
$ 16.45万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8608605 - 财政年份:2010
- 资助金额:
$ 16.45万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
7783286 - 财政年份:2010
- 资助金额:
$ 16.45万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8217143 - 财政年份:2010
- 资助金额:
$ 16.45万 - 项目类别:
Characterization of Presynaptic Protein Nerve wracked
突触前蛋白神经损伤的表征
- 批准号:
6529744 - 财政年份:2001
- 资助金额:
$ 16.45万 - 项目类别:
Characterization of Presynaptic Protein Nerve wracked
突触前蛋白神经损伤的表征
- 批准号:
6616700 - 财政年份:2001
- 资助金额:
$ 16.45万 - 项目类别:
Characterization of Presynaptic Protein Nerve wracked
突触前蛋白神经损伤的表征
- 批准号:
6405037 - 财政年份:2001
- 资助金额:
$ 16.45万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 16.45万 - 项目类别:
Research Grant